Odyssey Health
Odyssey Health Inc. is a specialty medical company focused on developing and commercializing life-saving medical products and health-related technologies. The company's mission is to address unmet medical needs through innovative solutions, including intranasal drugs for neurological conditions, cardiovascular mapping technology, and choking rescue devices. Odyssey aims to create, acquire, and advance unique assets and technologies with a focus on technological advantage, clinical utility, and market potential.
Industries
Nr. of Employees
small (1-50)
Odyssey Health
Las Vegas, Nevada, United States, North America
Products
Point-of-care cardiac monitoring and screening system (prototype)
A portable cardiac monitoring and screening device under development intended to produce enhanced sensitivity cardiac measurements, 3D visualizations to supplement standard ECG outputs, and rapid web-based analysis for remote and home screening.
Mechanical choking rescue device (prototype)
A device under development intended to provide a non-pharmaceutical intervention for clearing airway obstruction in choking events.
CardioMap
CardioMap is an advanced, highly portable point-of-care cardiac diagnostic and screening device designed to provide early, non-invasive testing of heart disease and stress levels in under 60 seconds with web-based analysis.
Save-A-Life Rescue Device
A patented anti-choking device currently in development featuring a pump for creating negative pressure and a replaceable mouthpiece to safely remove lodged objects from a choking victim's throat.
Point-of-care cardiac monitoring and screening system (prototype)
A portable cardiac monitoring and screening device under development intended to produce enhanced sensitivity cardiac measurements, 3D visualizations to supplement standard ECG outputs, and rapid web-based analysis for remote and home screening.
Mechanical choking rescue device (prototype)
A device under development intended to provide a non-pharmaceutical intervention for clearing airway obstruction in choking events.
CardioMap
CardioMap is an advanced, highly portable point-of-care cardiac diagnostic and screening device designed to provide early, non-invasive testing of heart disease and stress levels in under 60 seconds with web-based analysis.
Save-A-Life Rescue Device
A patented anti-choking device currently in development featuring a pump for creating negative pressure and a replaceable mouthpiece to safely remove lodged objects from a choking victim's throat.
Services
Execution and oversight of Phase I SAD and MAD studies conducted in collaboration with contract research organizations and clinical trial networks, including randomized, double-blind, placebo-controlled designs and safety review committee oversight.
Execution and oversight of Phase I SAD and MAD studies conducted in collaboration with contract research organizations and clinical trial networks, including randomized, double-blind, placebo-controlled designs and safety review committee oversight.
Expertise Areas
- Intranasal drug delivery
- Neuropharmacology for traumatic brain injury
- Preclinical TBI models and behavioral pharmacology
- Early-phase clinical development (Phase I SAD/MAD)
Key Technologies
- Breath-propelled intranasal delivery devices
- Spray-dried nanoparticle formulations
- Heat-stable powder formulations
- Preclinical concussion/TBI animal models
News & Updates
Odyssey Health, Inc. provided an update on its Asset Purchase Agreement with Oragenics, Inc., including details about shares and cash involved, and strategic benefits of the transaction.
Odyssey Health's stock commenced trading on the OTCQB Market after up-listing from OTC Pink Market, marking a milestone in its development programs.
Odyssey announced the successful completion of all cohorts in its Phase I clinical trial for PRV-002, a drug to treat concussion, demonstrating safety and tolerability.
Odyssey announced positive safety results from the first group of patients dosed with PRV-002 in their Phase I clinical trial for concussion.
Odyssey Health, Inc. provided an update on its Asset Purchase Agreement with Oragenics, Inc., including details about shares and cash involved, and strategic benefits of the transaction.
Odyssey Health's stock commenced trading on the OTCQB Market after up-listing from OTC Pink Market, marking a milestone in its development programs.
Odyssey announced the successful completion of all cohorts in its Phase I clinical trial for PRV-002, a drug to treat concussion, demonstrating safety and tolerability.
Odyssey announced positive safety results from the first group of patients dosed with PRV-002 in their Phase I clinical trial for concussion.